Biosimilar Reference Antibody-GS40121

货号：GS40121

Casdozokitug (CHS-388) is a potential first-in-class, human monoclonal antibody drug developed by Coherus BioSciences in the United States. As an immunotherapeutic agent, it is designed to modulate the tumor microenvironment by targeting a specific cytokine. Its primary mechanism involves blocking this cytokine's activity to alleviate immune suppression and thereby enhance the body's anti-tumor immune response.